Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

A pharmacokinetic study of lipegfilgrastim in children with Ewing family of tumors or rhabdomyosarcoma.

Belogurova MB, Kizyma ZP, Garami M, Csóka M, Lamson MJ, Buchner A, Bias P, Lammerich A.

Cancer Chemother Pharmacol. 2017 Jan;79(1):155-164. doi: 10.1007/s00280-016-3216-2. Epub 2016 Dec 16.

2.

Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients.

Volovat C, Bondarenko I, Gladkov O, Buchner A, Lammerich A, Müller U, Bias P.

Support Care Cancer. 2016 Dec;24(12):4913-4920. Epub 2016 Aug 8.

PMID:
27501966
3.

Comment on "Biosimilar FSH preparations- are they identical twins or just siblings?"

Strowitzki T, Kuczynski W, Mueller A, Bias P.

Reprod Biol Endocrinol. 2016 Sep 26;14(1):63. No abstract available.

4.
5.

Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.

Pettengell R, Bias P, Mueller U, Lang N.

Support Care Cancer. 2016 Jun;24(6):2677-84. doi: 10.1007/s00520-015-3057-2. Epub 2016 Jan 16.

PMID:
26780505
7.

Cardiovascular Morbidity and Pure Red Cell Aplasia Associated With Epoetin Theta Therapy in Patients With Chronic Kidney Disease: A Prospective, Noninterventional, Multicenter Cohort Study.

Lammerich A, Balcke P, Bias P, Mangold S, Wiesholzer M.

Clin Ther. 2016 Feb;38(2):276-287.e4. doi: 10.1016/j.clinthera.2015.11.018. Epub 2015 Dec 19.

PMID:
26708119
9.
10.

Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy.

Volovat C, Bondarenko IM, Gladkov OA, Elsässer R, Buchner A, Bias P, Müller U.

Springerplus. 2015 Jul 3;4:316. doi: 10.1186/s40064-015-1067-7. eCollection 2015.

11.

Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.

Gladkov OA, Buchner A, Bias P, Müller U, Elsässer R.

Support Care Cancer. 2016 Jan;24(1):395-400. doi: 10.1007/s00520-015-2803-9. Epub 2015 Jun 20.

PMID:
26092233
12.

Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.

Bondarenko IM, Bias P, Buchner A.

Support Care Cancer. 2016 Jan;24(1):267-73. doi: 10.1007/s00520-015-2777-7. Epub 2015 May 30.

PMID:
26024743
13.

Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.

Gladkov O, Moiseyenko V, Bondarenko IN, Shparyk Y, Barash S, Adar L, Bias P, Avisar N.

Med Oncol. 2015 Jun;32(6):623. doi: 10.1007/s12032-015-0623-x. Epub 2015 May 13.

PMID:
25966791
14.

A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.

Buchner A, Elsässer R, Bias P.

Breast Cancer Res Treat. 2014 Nov;148(1):107-16. doi: 10.1007/s10549-014-3120-6. Epub 2014 Sep 27.

15.

Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers.

Buchner A, Lammerich A, Abdolzade-Bavil A, Müller U, Bias P.

Curr Med Res Opin. 2014 Dec;30(12):2523-33. doi: 10.1185/03007995.2014.962131. Epub 2014 Sep 25.

PMID:
25251999
16.

Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy.

Volovat C, Gladkov OA, Bondarenko IM, Barash S, Buchner A, Bias P, Adar L, Avisar N.

Clin Breast Cancer. 2014 Apr;14(2):101-8. doi: 10.1016/j.clbc.2013.10.001. Epub 2013 Oct 25.

PMID:
24485296
17.
18.

Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta.

Gertz B, Kes P, Essaian A, Bias P, Buchner A, Zellner D.

Curr Med Res Opin. 2012 Jul;28(7):1101-10. doi: 10.1185/03007995.2012.688736. Epub 2012 May 23.

PMID:
22533679
19.

Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial.

Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A.

Arch Drug Inf. 2011 Sep;4(3):33-41.

20.

Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial.

Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A.

Arch Drug Inf. 2010 Sep;3(3):45-53.

Supplemental Content

Loading ...
Support Center